Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | RXRB | P28702 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824453 | 0.83 | NPC1 (0.59) | MAP4K4TSHRBCL2L1BADMKNK1 | |
| SCHEMBL1109095 | 0.82 | NAPRT (0.71) | RXRARXRBMAP4K4NAPRTTSHR | |
| SCHEMBL1867850 | 0.80 | MAP4K4 (0.57) | MAP4K4BCL2L1BADMKNK1MKNK2 | |
| SCHEMBL28402774 | 0.80 | TSHR (0.75) | RXRARXRBNAPRTTSHRALOX15 | |
| SCHEMBL63857 | 0.78 | NAPRT (0.58) | NAPRTTSHRALOX15TP53 | |
| SCHEMBL30213522 | 0.78 | P4HA1 (0.69) | MAP4K4TSHRBCL2L1BADMKNK1 | |
| SCHEMBL31084434 | 0.78 | P4HA1 (0.69) | MAP4K4TSHRBCL2L1BADMKNK1 | |
| SCHEMBL20704770 | 0.78 | P4HA1 (0.69) | MAP4K4TSHRBCL2L1BADMKNK1 | |
| SCHEMBL2637326 | 0.78 | TSHR (0.80) | RXRARXRBNAPRTTSHRALOX15 | |
| Terephthalic Acid SCHEMBL9577834 | 0.78 | TSHR (0.80) | RXRARXRBNAPRTTSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| EP-1928236-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM, LLC (BM) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038669-A9 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC | 2008-05-29 | — | — | WO | disclosed |
| WO-2007038669-A9 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC | 2008-05-29 | — | — | WO | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | RXRA 2236/4885RXRB 2049/4885MAP4K4 598/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | RXRA 2236/4885RXRB 2049/4885MAP4K4 598/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | RXRA 2236/4885RXRB 2049/4885MAP4K4 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.